Mehmet Sezai TAŞBAKAN, Yelda ÇEVİKER, Oğuz Reşat SİPAHİ, Dilek METİN, Ali VERAL, Alev SUSUR, Abdullah SAYINER, Feza BACAKOĞLU

Pansitopenik bir olguda rinoserebral ve akciğer mukormikozu ve aspergillozu

Mukormikoz, nadir ve sıklıkla ölümcül seyreden bir invazif fungal infeksiyondur. Bağışıklığı baskılanmış hastalarda genellikle dissemine veya pulmoner formlar görülürken, diyabetik hastalarda genellikle rinoserebral form görülür. Bu yazıda, hematolojik malignite nedeniyle kemoterapi alan 50 yaşındaki kadın hastada gelişen bir rinoserebral ve pulmoner mukormikoz ile invazif pulmoner aspergilloz olgusu sunulmuştur. Olgumuz uygun antifungal tedaviye yanıt vermemiş ve kaybedilmiştir. Rinoserebral ve pulmoner mukormikoz ile pulmoner aspergilloz birlikteliği nadir bir durumdur. Agresif tıbbi ve cerrahi tedaviye rağmen, mortalite oranları yüksektir.

Concomitant rhinocerebral and pulmonary mucormycosis and invasive pulmonary aspergillosis in a pancytopenic patient

Mucormycosis is a rare and often fatal invasive fungal infection. While disseminated or pulmonary forms are common in patients with immune insufficiency, rhinocerebral form is common in diabetes mellitus patients. In this paper we present a case with rhinocerebral and pulmonary mucormycosis and invasive pulmonary aspergillosis in a 50-year old female patient who received chemotherapy due to haematological malignancy. The patient was lost in spite of appropriate antifungal therapy. Rhinocerebral and pulmonary mucormycosis and concomittant pulmonary aspergillosis is a very rare case. Despite aggressive medical and surgical treatment mortality rates are high.

PDF

___

1. Çoşkun H, Heper Y, Hızalan İ, Erişen L, Basut O, Akalın H: Rino-serebral mukormikozis: Üç olgu sunumu, Türk Otolarengoloji Arşivi 2004;42(1):41-50.
2. De Pauw B, Walsh TJ, Donnelly JP et al: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis 2008;46(12):1813-21.
3. Deboni MC, Pozzani VR, Lisboa T, Hiraki K, Viplich R, Naclério-Homem MG: Mucormycosis in an immunocompetent patient: follow-up of 1 year after treatment, Acta Otolaryngol 2006; 126(9):993-6.
4. Erkaleli M, Alacacıoğlu İ, Payzın B, Ermete M, Arslan SL: Kraniofasiyal mukormikoz: Bir olgu sunumu, Fırat Tıp Derg 2009;14(3):210-2.
5. Kandemir Ö, Görür K, Şahin E, Özcan C, Düşmez Apa D: The probable role of desferrioxamine for rhinocerebral mucormycosis in a diabetic patient, ANKEM Derg 2007;21(4):237-41.
6. Lee FY, Mossad SB, Adal KA: Pulmonary mucormycosis. The last 30 years, Arch Intern Med 1999;159(12):1301-9.
7. Oktay MF, Yıldırım M: İki olgu nedeniyle mukormikozis, Dicle Tıp Derg 2007;34(3):211-5.
8. Sugar MA: Agents of mukormycosis and relates species, “Mandell GL, Bennett JE, Dolin R: Infectious Diseases, Sixth edition” kitabında s.2973-84, Churchill Livingstone, Philadelphia (2005).
9. Taşbakan MI, Arda B, Soyer NA ve ark: Aplastik anemili bir olguda mukormikoz, Ege Tıp Derg 2007;46(1):57-60.
10. Yıldırım M, Yorgancılar E, Topçu İ, Meriç F: Rino-serebral mukormikozis: Palatal nekroz, KBB-Forum 2009;8(3):75-8.